In addition, since rapid androgen actions have been reported in classical AR-lacking breast cancer models [33] and membrane androgen binding sites have been observed in breast carcinoma cells [34], OXER1 has been recently proposed as a potential drug target in breast cancer [35]. This evidence concerns the gene AR and breast carcinoma.